Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer
Launched by MAASTRICHT RADIATION ONCOLOGY · Mar 10, 2010
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Biobank Carcinoma," is studying how the DNA and protein in the blood of cancer patients might relate to important outcomes, like how long patients live and the side effects they experience from their treatments. By analyzing these biological markers, researchers hope to gain insights that could help improve cancer care in the future.
To participate in this study, you need to be diagnosed with cancer and be between the ages of 65 and 74. If you join the trial, you’ll provide blood samples that will be analyzed for your DNA and protein levels. It’s important to note that you must be able to keep up with follow-up visits to stay in the study. This research is still recruiting participants, so if you're interested or know someone who might be eligible, it could be a valuable opportunity to contribute to cancer research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • cancer
- Exclusion Criteria:
- • not able to comply with follow-up
About Maastricht Radiation Oncology
Maastricht Radiation Oncology is a leading clinical trial sponsor dedicated to advancing the field of radiotherapy through innovative research and development. Based in Maastricht, the Netherlands, the organization specializes in conducting high-quality clinical trials that aim to improve treatment outcomes for cancer patients. With a strong emphasis on collaboration and multidisciplinary approaches, Maastricht Radiation Oncology integrates cutting-edge technology and evidence-based methodologies to explore novel therapeutic strategies. Their commitment to patient-centered care and rigorous scientific standards positions them at the forefront of oncology research, driving progress in cancer treatment and management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, Limburg, Netherlands
Patients applied
Trial Officials
Dirk De Ruysscher, Prof PHD
Principal Investigator
CCMO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials